Table 1 General data of study subjects.
Variable | Overall (n = 14,412) | 2020–2022 (n = 5106) | 2023 (n = 9306) | p-value |
|---|---|---|---|---|
Age, median (IQR), year | 7.00 [3.00, 29.00] | 4.00 [2.00, 9.00] | 8.00 [4.00, 35.00] | < 0.001 |
Sex, n (%) | 0.031 | |||
Male | 7567 (52.50) | 2766 (54.17) | 4801 (51.59) | |
Female | 6845 (47.50) | 2340 (45.83) | 4505 (48.41) | |
Age group, n (%) | < 0.001 | |||
Infants and toddlers (0−3years) | 4009 (27.82) | 2216 (43.40) | 1793 (19.27) | |
Children (4−6years) | 3094 (21.47) | 1146 (22.44) | 1948 (20.93) | |
Adolescents (7−17years) | 3273 (22.71) | 728 (14.26) | 2545 (27.35) | |
Adults (18−59years) | 2136 (14.82) | 497 (9.73) | 1639 (17.61) | |
Old-aged (≥ 60years) | 1900 (13.18) | 519 (10.16) | 1381 (14.84) | |
Positive rate, n (%) | ||||
IFV-A | 2141 (14.86) | 81 (1.59) | 2060 (22.14) | < 0.001 |
IFV-B | 310 (2.15) | 78 (1.53) | 232 (2.49) | < 0.001 |
HBoV | 191 (1.33) | 72 (1.41) | 119 (1.28) | 0.560 |
HMPV | 828 (5.75) | 248 (4.86) | 580 (6.23) | < 0.001 |
HRV | 2382 (16.53) | 892 (17.47) | 1490 (16.01) | 0.026 |
HPIV | 728 (5.05) | 225 (4.41) | 503 (5.41) | 0.009 |
HCoV | 328 (2.28) | 73 (1.43) | 255 (2.74) | < 0.001 |
RSV | 747 (5.18) | 346 (6.78) | 401 (4.31) | < 0.001 |
HAdV | 539 (3.74) | 201 (3.94) | 338 (3.63) | 0.381 |
Mp | 1993 (13.83) | 208 (4.07) | 1785 (19.18) | < 0.001 |
